Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC
RS Herbst, A Sandler - The Oncologist, 2008 - academic.oup.com
Biologic agents that target molecules involved in tumor growth, progression, and
pathological angiogenesis—such as the human epidermal growth factor receptor (EGFR) …
pathological angiogenesis—such as the human epidermal growth factor receptor (EGFR) …
Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC.
RS Herbst, A Sandler - The Oncologist, 2008 - europepmc.org
Biologic agents that target molecules involved in tumor growth, progression, and
pathological angiogenesis--such as the human epidermal growth factor receptor (EGFR) …
pathological angiogenesis--such as the human epidermal growth factor receptor (EGFR) …
[PDF][PDF] Bevacizumab and Erlotinib: A Promising New Approach to the Treatment of Advanced NSCLC
ROYS HERBST, A SANDLER - The Oncologist, 2008 - Citeseer
Biologic agents that target molecules involved in tumor growth, progression, and
pathological angiogenesis—such as the human epidermal growth factor receptor (EGFR) …
pathological angiogenesis—such as the human epidermal growth factor receptor (EGFR) …
Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC
RS Herbst, A Sandler - The oncologist, 2008 - pubmed.ncbi.nlm.nih.gov
Biologic agents that target molecules involved in tumor growth, progression, and
pathological angiogenesis--such as the human epidermal growth factor receptor (EGFR) …
pathological angiogenesis--such as the human epidermal growth factor receptor (EGFR) …
[PDF][PDF] Bevacizumab and Erlotinib: A Promising New Approach to the Treatment of Advanced NSCLC
RS Herbst, A Sandler - The Oncologist, 2008 - Wiley Online Library
Biologic agents that target molecules involved in tumor growth, progression, and
pathological angiogenesis—such as the human epidermal growth factor receptor (EGFR) …
pathological angiogenesis—such as the human epidermal growth factor receptor (EGFR) …
Bevacizumab and Erlotinib: A Promising New Approach to the Treatment of Advanced NSCLC.
ROYS HERBST, A SANDLER - Oncologist, 2008 - search.ebscohost.com
Biologic agents that target molecules involved in tumor growth, progression, and
pathological angiogenesis--such as the human epidermal growth factor receptor (EGFR) …
pathological angiogenesis--such as the human epidermal growth factor receptor (EGFR) …
Bevacizumab and Erlotinib: A Promising New Approach to the Treatment of Advanced NSCLC
RS Herbst, A Sandler - The Oncologist, 2008 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Biologic agents that target molecules involved
in tumor growth, progression, and pathological angiogenesis—such as the human …
in tumor growth, progression, and pathological angiogenesis—such as the human …
[PDF][PDF] Bevacizumab and Erlotinib: A Promising New Approach to the Treatment of Advanced NSCLC
ROYS HERBST, A SANDLER - Citeseer
Biologic agents that target molecules involved in tumor growth, progression, and
pathological angiogenesis—such as the human epidermal growth factor receptor (EGFR) …
pathological angiogenesis—such as the human epidermal growth factor receptor (EGFR) …